Fenwick represented Prelude Therapeutics (NASDAQ: PRLD), a clinical-stage precision oncology company, in its upsized public offering of 2,583,334 shares of its voting common stock and 291,666 shares of its non-voting common stock, each at a public offering price of $60.00 per share, which includes the exercise in full of the underwriters’ option to purchase an additional 375,000 shares of its voting common stock. The aggregate gross proceeds from this offering were $172.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Prelude.
Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities and Barclays acted as joint book-running managers for the offering. More information can be obtained from Prelude’s announcement.
The transaction was led by corporate partners Robert Freedman and Effie Toshav and included partner Julia Forbess and associates Alice Lin, Emily Yi and John Clancy. In 2020, Fenwick also represented Prelude in its initial public offering.